Hàn Quốc cấp phép khẩn cấp thuốc molnupiravir điều trị COVID-19

Trong nỗ lực giảm ca bệnh nặng và tử vong do COVID-19, cơ quan an toàn dược phẩm của Hàn Quốc ngày 23/3 đã cấp phép khẩn cấp thuốc molnupiravir của hãng Merck & Co Inc để điều trị cho người trưởng thành mắc COVID-19.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Ấn Độ thử thành công rocket dẫn đường tầm xa, phê duyệt mua sắm quốc phòng trị giá hơn 8 tỷ USD

Ấn Độ thử thành công rocket dẫn đường tầm xa, phê duyệt mua sắm quốc phòng trị giá hơn 8 tỷ USD

Thế giới
(Baothanhhoa.vn) - Ấn Độ vừa thử nghiệm thành công lần đầu rocket dẫn đường tầm xa Pinaka, đồng thời phê duyệt gói mua sắm quốc phòng trị giá hơn 8 tỷ USD, cho thấy nỗ lực mạnh mẽ của nước này trong việc nâng cao năng lực tác chiến chính xác và hiện đại hóa lực lượng vũ trang.
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh